Business Matters: Eclipsed by Catastrophe

Publication
Article
BioPharm InternationalBioPharm International-11-01-2001
Volume 14
Issue 11

by G. Steven Burrill at Burrill & Company Despite stimulating and positive news for biotech product approvals and high-value deals this quarter, market performance has been shaped by the terrorist attacks and their aftermath.

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Junevity Co-founder & CEO, John Hoekman, PhD
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Daniel Fischer, Tevard
Related Content
© 2025 MJH Life Sciences

All rights reserved.